EXAC Exactech Inc. featured news, full reports, and detailed charts
Exactech Inc. (EXAC) Wrap Up:
Exactech, Inc. engages in the development, manufacture, marketing, distribution, and sale of orthopedic implant devices, related surgical instrumentation, and biologic services to hospitals and physicians in the United States and internationally. It offers joint replacement systems, including knee, upper extremity, and hip implant systems, as well as biologic allograft services and bone cement materials used in orthopedic surgery. Its joint replacement products are used by orthopedic surgeons to repair or replace joints that have deteriorated as a result of injury or disease. The company’s product portfolio comprises Optetrak knee system that serves orthopedic surgeons in contact stress, pat...Exactech Inc. (EXAC:NASDAQ)
Snapshot of Exactech Inc. (EXAC)
|
OPEN
$16.17
|
PREVIOUS CLOSE
$16.17
|
|
|
DAY HIGH
$16.40
|
DAY LOW
$16.02
|
|
|
52 WEEK HIGH
12/8/08 - $18.61
|
52 WEEK LOW
03/19/09 - $10.74
|
|
|
MARKET CAP
206.9M
|
AVERAGE VOLUME 3 mo
34.6K
|
|
|
DILUTED EPS TTM
$0.85
|
SHARES OUTSTANDING
12.8M
|
|
|
EXAC Does Not Pay Dividends
|
P/E TTM
19.1x
|
|
| K = Thousands M = Millions B = Billions | ||
EXAC Top Compensated Officers
Executives, Board Directors
Key developments for Exactech Inc. (EXAC)
Exactech Inc. announced unaudited consolidated earnings results for the third quarter and nine months ended September 30, 2009. Total revenue for the third quarter of 2009 increased 12% to $42.4 million from $37.9 million in the third quarter of 2008. Diluted earning per share for the quarter was $0.21 based on net income of $2.7 million. This compares with net income of $2.1 million or $0.16 diluted EPS a year ago. Net income for the quarter excluding pre-tax legal expenses and costs of $845,000 related to the ongoing Department of Justice (DOJ) inquiry, was $3.3 million or $0.25 EPS. Income from operations was $4.4 million against $4 million and income before income tax was $4.4 million against $3.7 million reported last year. For the first nine months of 2009 revenue was $129.0 million, an increase of 6% over $121.4 million for the comparable period last year. Net income for the first nine months of 2009 was $7.8 million representing a 2% decrease from the first nine months of 2008. Diluted earning per share was $0.61 against $0.63 reported last year. Net income for the nine months, excluding pre-tax legal expenses and costs of $3.4 million related to the ongoing Department of Justice (DOJ) inquiry, was $10.0 million or $0.77 diluted EPS. Income from operations was $12.8 million against $14 million and income before income tax was $12.5 million against $13.5 million reported last year. Exactech increased its revenue targets for 2009 in the range of $171 million to $174 million and now targets diluted earnings per share for the year 2009 in the range of $1.00 to $1.02. For the fourth quarter ending December 31, 2009, the company expected to report revenue in the range of $42 million to $45 million and diluted earnings per share in the range of $0.22 to $0.24. These EPS target ranges exclude the impact of DOJ inquiry costs.
Exactech Inc. expected to Report Fiscal Year 2009 Results on February 15, 2010. This event was calculated by Capital IQ (Created on October 27, 2009).
Exactech Inc., Q3 2009 Earnings Call, Oct 28 2009
EXAC Competitors
| Company | Last | Change |
| Cryolife Inc | $6.11 USD | +0.12 |
| Integra LifeSciences Holdings Corp | $31.99 USD | +0.41 |
| ReGen Biologics Inc | $0.50 USD | 0.00 |
| Wright Medical Group Inc | $18.39 USD | +0.39 |
| Market data is delayed at least 20 minutes. | ||
Industry Analysis
| Valuation | EXAC | Industry Range |
| Price/Earnings | 19.0x |
|
| Price/Sales | 1.2x |
|
| Price/Book | 1.6x |
|
| Price/Cash Flow | 10.5x |
|
| TEV/Sales | 1.1x |
|
|
EXAC |
||
EXAC transactions
| Type Date |
Target | |
| No transactions in the last 6 months. | ||